In The News: Department of Brain Health

MarketWatch
November 4, 2019

China has approved its first homegrown Alzheimer’s treatment — a novel drug based on algae, and the first breakthrough since 2003 in a field that has frustrated scientists and drug companies for decades.

Yahoo!
November 4, 2019

Shanghai Green Valley Pharmaceuticals (Green Valley) today announced that China's National Medical Products Administration (NMPA) has approved Oligomannate (GV-971) as new drug for the treatment of "mild to moderate Alzheimer's disease (AD) and improving cognitive function."

PR Newswire
November 4, 2019

Shanghai Green Valley Pharmaceuticals (Green Valley) announced today that China's National Medical Products Administration ( ANPM ) has approved oligo manato (GV-971) as a new drug for treatment of "Alzheimer's disease (AD) from benign to moderate and to improve cognitive function".

PR Newswire
November 2, 2019

Shanghai Green Valley Pharmaceuticals (Green Valley) today announced that China's National Medical Products Administration (NMPA) has approved Oligomannate (GV-971) as new drug for the treatment of "mild to moderate Alzheimer's disease (AD) and improving cognitive function."

KVVU-TV: Fox 5
October 19, 2019

Promising research is coming out of a new department at the University of Nevada, Las Vegas focused on brain health.

DailyHeralds
September 17, 2019

Dr. Jeffrey Cummings, a world-renowned Alzheimer's researcher and leader in clinical trials, has been named the recipient of the 2019 Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery. The prize, awarded by the Alzheimer's Drug Discovery Foundation (ADDF), recognizes leading researchers developing treatments for Alzheimer's disease and related dementias.

Deer Park Tribune
September 17, 2019

Dr. Jeffrey Cummings, a world-renowned Alzheimer's researcher and leader in clinical trials, has been named the recipient of the 2019 Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery. The prize, awarded by the Alzheimer's Drug Discovery Foundation (ADDF), recognizes leading researchers developing treatments for Alzheimer's disease and related dementias.

NeurologyLive
August 19, 2019

An expert panel reviews the causes of Alzheimer disease, as well as strategies used to detect mild cases and cognitive impairment.

NeurologyLive
August 15, 2019

At the American Academy of Neurology Annual Meeting held in Philadelphia, Pennsylvania, Jeffrey L. Cummings, MD, ScD, the director emeritus of the Cleveland Clinic Lou Ruvo Center for Brain Health and vice chair of the department of brain health at the University of Nevada Las Vegas, spoke with NeurologyLive in an interview to discuss therapies currently being investigated for the treatment of Alzheimer disease.

MD Magazine
July 30, 2019

The Cleveland Clinic’s fourth annual Alzheimer disease (AD) drug development pipeline presents a new round of clinical trials to give clinicians a comprehensive look at current research in the US. The investigators, led by Jeffrey Cummings, MD, ScD, director emeritus of Cleveland Clinic Lou Ruvo Center for Brain Health, identified all pharmacologic Alzheimer trials currently in development from Clinicaltrials.gov. They found 132 agents currently in 156 clinical trials— 28 of which are in 42 phase 3 trials; 74 in 83 phase 2 trials; and 30 in 31 phase 1 trials.

NeurologyLive
July 29, 2019

At the 2019 American Academy of Neurology Annual Meeting in Philadelphia, Pennsylvania, Jeffrey Cummings, MD, ScD, director emeritus of the Cleveland Clinic Lou Ruvo Center for Brain Health and vice chair for department of brain health at the University of Nevada Las Vegas, spoke with NeurologyLive in an interview to discuss several hot topics in Alzheimer disease.

EurekAlert!
July 11, 2019

Cleveland Clinic's fourth annual analysis of Alzheimer's disease drug development found that the pipeline has grown in the number and variety of agents being tested over the past year, while highlighting several advances in the field including new clinical trial designs, more detailed criteria for making a research diagnosis, and an increased use of biological tests reflecting of the disease.